Assessment of a Neck-based Treatment and Monitoring Device for Positional Obstructive Sleep Apnea

Daniel J Levendowski, MBA¹, Sean Seagraves, BS¹, Djordje Popovic, MD¹, Philip R. Westbrook, MD¹

¹Advanced Brain Monitoring, Inc., Carlsbad, California (USA).

Abstract word count: 250
Total word count: 5604

Institution where the work was performed: Advanced Brain Monitoring, Inc. and Complete Sleep Solutions, Murrieta, CA.

Disclosures related to this work: The study was funded by Advanced Brain Monitoring, Inc. All authors are salaried employees of Advanced Brain Monitoring, Inc., the sponsor of this research. As co-inventors of the neck-device, Levendowski, Popovic and Westbrook would only benefit financially if the Night Shift intellectual property was acquired by a third party. None of the authors with this conflict were involved with subject recruitment, data acquisition or data reduction. The results summarized and reported by these authors were submitted to the U.S. Food and Drug Administration whereby civil or criminal penalties apply for untruthful and inaccurate statements. Complete Sleep Solutions was paid the standard fee for each PSG study and an hourly rate for performance of study-related recruitment tasks.

Corresponding Author:
Daniel Levendowski, MBA
Advanced Brain Monitoring, Inc.
2237 Faraday Avenue, Suite 100
Carlsbad, CA, USA 92008

Tel: 1 760 720-0099

Fax: 1 760 476-3620

Email: Dan@b-alert.com
ABSTRACT

Study Objectives:

A majority of patients diagnosed with obstructive sleep apnea are position dependent whereby they are at least twice as severe when sleeping supine (POSA). This study evaluated the accuracy and efficacy of a neck-worn device designed to limit supine sleep. The study included nightly measurements of snoring, sleep/wake, time supine, and the frequency and duration of feedback to monitor compliance.

Methods:

Thirty patients between ages 18 and 75 years, BMI<35 with an overall apnea-hypopnea index (AHI)>5 and an overall AHI>1.5 time the non-supine AHI, and an Epworth score >5 were prospectively studied. Subjective reports and polysomnography were used to assess efficacy resulting from four-weeks of in-home supine-avoidance therapy and to measure device accuracy. From 363 polysomnography reports, 209 provided sufficient positional data to estimate one site’s prevalence of positional OSA.

Results:

In eighty-three percent of participants exhibiting >50% reduction in overall AHI, the mean and median reductions were 69 and 79%. Significant reductions in the overall and supine AHI, apnea index, percent time SpO2<90%, and snoring contributed to significant improvements in stage N1 and N2 sleep, reductions in cortical arousals and awakenings, and improved depression scores. Supine position was under-detected by >5% in 3% of cases. Sleep efficiency by neck actigraphy was within 10% of polysomnography in 87% of the studies when position feedback was delivered. The prevalence of POSA was consistently >70% when the overall AHI was <60.
Conclusions:

The neck position therapy device is accurate and effective in restricting supine sleep, improving AHI, sleep architecture and continuity, and monitoring treatment outcomes.

Key words: Obstructive sleep apnea, positional therapy, supine sleep, snoring, prevalence

Brief Summary Box:

Current Knowledge/Study Rationale:

Obstructive sleep apnea is now quite easy to diagnose but remains difficult to treat when both efficacy and compliance are considered. In this prospective study, we evaluated the impact of four weeks of neck-based vibro-tactile positional therapy on respiratory and sleep architecture measures, subjective symptoms, and compliance in patients with mild, moderate and severe positional obstructive sleep apnea (POSA).

Study Impact:

We found position therapy significantly reduced sleep disordered breathing and significantly improved sleep quality and moderately reduced symptoms across all OSA severity groups. The prevalence of POSA was relatively consistent across all patients who had an overall AHI <60 events/hour.
INTRODUCTION:

Obstructive sleep apnea (OSA) is a common chronic human affliction that is now quite easily
diagnosed but remains difficult to treat. The vast majority of OSA patients have more obstructive events
in the supine position, where gravity aids the collapsing forces on the upper airway.\(^1\) Also, compared to
other recumbent positions, supine sleep reduces end-expiratory lung volume, which in turn decreases
tracheal tug and lung oxygen stores, and contributes to greater hypoxemia during each obstructive
breathing event. A formal diagnosis of positional OSA (POSA) is made when the difference between the
apnea-hypopnea index (AHI) in the supine and non-supine positions exceeds one of the cutoff points
defined in the literature.\(^1-6\) The prevalence of POSA among OSA patients is estimated at 56\(^\%\)^\(^3-4\) if the
standard definition of POSA by Cartwright (i.e. at least a twofold difference between the supine and
non-spine AHI) is used.\(^6\)

Clinical studies have demonstrated that position therapy can reduce the AHI to the “normal”
range of less than 5 events per hour in some patients with POSA irrespective of the disease severity.\(^7\)
This suggests that if someone has clinically important OSA when supine, but has a relatively low AHI
when non-supine, then keeping that person from sleeping supine could be the only treatment needed.
The early versions of position therapy used objects of various sizes and shapes strapped to the patients
back to make the supine position too uncomfortable to be maintained.\(^7,8\) Unfortunately, such an
approach limits comfortable sleep, and similar to continuous positive airway pressure (CPAP),
discomfort can result in poor long term compliance.\(^9\) More recently, vibro-tactile feedback from small
devices have been introduced as a more sleep-friendly therapeutic intervention for POSA.\(^10-12\) The
additional benefit of ‘electronic’ position therapy approaches is that, like CPAP, utilization and
effectiveness can potentially be monitored.

This study provides an initial prospective evaluation of a neck-worn device that delivers vibro-
tactile feedback as a deterrent to supine sleep. The primary endpoints include an evaluation of the
effect of four-weeks of position therapy on respiratory, sleep architecture and subjective measures. Secondary endpoints include an assessment of the accuracy of neck-based actigraphy for the detection of sleep position and estimation of sleep and wake time. Supporting evidence includes a demonstration of the device’s capability to monitor its utilization and effectiveness in the home. Finally, the prevalence of positional POSA in non-study patients evaluated by the study site with laboratory PSG while the study was ongoing is reported.

METHODS:

Protocol Design:

Volunteers were recruited under a protocol approved by the Chesapeake Institutional Review Board after review by the U.S. Food and Drug Administration (FDA). Enrollment required an age between 18 and 75 years, a screening overall apnea hypopnea index (AHI) > 10 (based on a previously completed PSG or home sleep test (HST)), an Epworth Sleepiness Score (ESS) ≥ 5, and a body mass index (BMI) ≤ 35 kg/m².

At the time of enrollment, subjects completed a battery of questionnaires to obtain pre-treatment measures of daytime sleepiness using the ESS, quality of life with the Functional Outcomes of Sleep Questionnaire (FOSQ) and Profile of Mood States (POMS), depression using the Patient Health Questionnaire (PHQ-9), insomnia using the Insomnia Severity Index (ISI), and anxiety by the Generalized Anxiety Disorder (GAD-7) questionnaire. In-home use of the Neck Position Therapy Device (NPTD) and generation of compliance reports were also explained.

To proceed onto therapy, volunteers needed to be diagnosed with POSA resulting from a baseline PSG with a minimum of four hours of sleep time, an overall AHI ≥ 5, and an overall AHI ≥ 1.5 times greater than the non-supine AHI. During the baseline PSG studies subjects wore the NPTD that was set to record-only mode (i.e., no positional feedback) and applied by the sleep technician. To
provide a means to synchronize the PSG and the NPTD records, subjects were instructed to sit upright in bed for one-minute just prior to lights out and just after lights on. Technicians were instructed to attempt to acquire equivalent amounts of supine and non-supine sleep from each subject.

For the position therapy period, subjects were instructed to wear the NPTD for 30-nights while in bed and attempting to sleep. The first two nights provided an adaptation period in which no feedback was delivered. This allowed participants the opportunity to withdraw prior to initiating 28 consecutive nights of NPTD therapy and being categorized with an intention to treat. Subjects maintained daily logs so that potential interruption to their day- or night-time quality of life attributed to the position therapy could be evaluated, and comparisons between self-reported use and compliance measured with the NPTD could be compared. To remain in the study, subjects were required to generate a compliance report on the NPTD web-portal and mail the daily logs at the end of each week. Upon completion of four weeks of therapy, subjects completed the post-treatment battery of questionnaires and continued to receive positional therapy until completion of the follow-up PSG.

**Polysomnography:**

All subjects were recruited from and studied at an American Academy of Sleep Medicine (AASM) accredited sleep center (Complete Sleep Solutions, Murrieta, CA). The baseline and follow-up PSG studies were conducted and scored according to the AASM criteria. Scoring of apneas required a 10-second cessation in breathing. Hypopneas required at least a 30% reduction in airflow combined with a 4% hypopnea desaturation. Subjects were studied in one of four rooms; two were equipped with Alice 3 and two with Alice 5 PSG systems (Philips Respironics, Monroeville, PA). Airflow was measured with Pro-Tech nasal pressure transducers. Respiratory effort was measured with Pro-Tech respiratory inductive plethysmography effort sensors. Chest position was measured with either Pro-Tech or SleepMate (Ambu, Inc. Glen Burke, MD) actigraphy-based position sensors. The Alice software synchronized and
saved the video recording with the physiological signals. During scoring of the studies, technicians used
video recordings to compare both torso and neck positions to the recorded chest position. Position
obtained from the chest transducer and confirmed by video (i.e., video/chest) was used for the PSG
report, and technician notes were used to identify periods when the chest was supine but the neck was
non-supine left/right (i.e., head was turned and neck elevated >30° from horizontal toward a lateral
position).

Description of the NPTD:

The battery-powered NPTD (Night Shift™, Advanced Brain Monitoring, Carlsbad, CA) weighs 44
grams and includes electronics housed in a 5.5 (l) x 3.8 (w) x 1.6 (h) cm enclosure affixed on the back of
the neck with an adjustable non-latex silicone rubber strap secured by a magnetic clasp (see Fig 1).14

The NPTD measures snoring with a built-in, calibrated acoustic microphone. The raw audio input
is sampled at 2 kHz, and root mean square (RMS) of the digitized signal is calculated using a 100 ms
window. The resulting 10 Hz RMS signal is additionally filtered with a 0.5Hz low-pass Butterworth 4th
order filter. A snore detection algorithm quantifies each snore based on the shape and the peak
amplitude, prior to conversion to decibels (db). Loud snoring is defined as at least one snore with a
magnitude ≥ 50 dB in a 30-second epoch. The percentage of time snoring >50 dB is then determined for
overall, supine, and non-supine epochs characterized as sleep by the NPTD.

A three-axis accelerometer is used to determine neck position and perform an actigraphy-based
classification of sleep vs. wake. Neck positions are reported as upright, supine, lateral left, lateral right,
and prone. Upright is assigned when the neck angle is ≥60°. Supine is assigned when the neck angle to
the left/right is <43°. Lateral left or right is assigned when the neck angle exceeded 47°. The NPTD
assumes the patient has remained in the previously assigned position when the neck angle falls between
43° and 47°. Prone is the mirrored position of supine with the additional requirement that the Z-axis is <
If the NPTD is worn upside down, the supine position will be accurately determined; however, reported time in the lateral left and right will be reversed. Thirty-second epochs are classified as sleep or wake by comparing the median filtered output derived from the three X, Y, and Z signals to a fixed threshold. If any of the three signals have an angle <50° and exceed the actigraphy threshold, the epoch is classified as wake. In addition, long periods with gross movement extend the wake classification for up to three subsequent ‘silent’ epochs. The initial ten-minute period after the NPTD is turned on is automatically classified as wake.

Two x 1G haptic motors provide vibro-tactile feedback when the supine position is detected. Positional feedback is modulated by setting the number of motors to be excited (one or both) and varying the duration of the motor(s) excitation. Feedback is initiated at a very low frequency/duration, and gradually increased until the user exits the supine position. At any given intensity level, the feedback is repeated three times with an inter-feedback interval of two-seconds. The feedback can be optionally paused for a pre-defined time interval or completely turned off. A total of seven levels of feedback are delivered with levels five through seven utilizing both haptic motors. For this study vibrotactile feedback was defaulted to initiate 15-minutes after the NPTD was turned on, to allow the user time to fall asleep. Upon conclusion of an upright period > 45-seconds, positional feedback was paused for 5-minutes.

Data are acquired and analyzed in real time with derived measures for sleep/wake, snoring magnitude, and position for each 30-second epoch saved to the microcontroller flash memory. The NPTD memory can store up to six nights’ of detailed snoring, sleep, and position measures (one set of values for each 30-second epoch), as well as a summary of key daily parameters by month for four months, and the average values across the days in the month for 12 months. All the information is accessed via assessment/compliance reports generated in HTML format from a web-enabled portal. The NPTD can record and provide vibro-tactile feedback for three nights before charging is required.
Data Reduction and Analysis:

In addition to the standard sleep study reports, Alice software was used to export epoch level resolution of chest position and sleep stage. To compare PSG and neck-device epoch classifications of sleep or wake, and supine or non-supine, the clock times from the files were aligned, with accurate synchronization confirmed by the change to the upright position at the start of the recording. The percentage of time supine, as determined by PSG (chest sensor and video recording) and NPTD (neck accelerometer) during the baseline and follow-up PSG studies, were compared from lights out to lights on. Video recordings were reviewed to provide the gold standard for classification of the supine position based on the neck at $< 30^\circ$ angle from horizontal. Technician notes from the video review during scoring were used to identify when technician edits were applied to the body position and when the neck position conflicted with body position. Bland-Altman plots were used to compare the supine sleep detection from the neck and chest. From the PSG hypnograms, the number of awakenings (return to an awake state from any rapid eye movement (REM) or non-REM sleep stage were tallied and divided by the hours of total sleep time.

Two-tailed t-tests, which assumed equal variances, were used to measure significant differences between baseline and follow-up respiratory, sleep architecture, sleep/wake and subjective measures. A minimum of 12-minutes of sleep time was required for supine AHI values to be reported as greater than zero. The overall percent time snoring $\geq 50$ dB from the neck (loud snoring) was computed from lights out to lights on during periods detected as sleep by neck (NPTD) actigraphy. Bland-Altman plots are used to compare differences in the total sleep time (TST), sleep efficiency (SE), sleep onset (SO), and wake after sleep onset (WASO) derived from the respective PSG and NPTD.

To assess position therapy compliance, the utilization rate was defined as the number of nights that the device was worn for a minimum of four hours divided by the days during the intention to treat.
period, similar to that used for CPAP.\textsuperscript{15} Repeated measures analysis of variance (ANOVA) was used to evaluate changes in utilization, efficacy, and response to feedback measured with the NPTD across the four-weeks of therapy. Repeated measures ANOVA was also used to evaluate changes across the daily sleep diary reports with respect to weekly changes in: a) average number of previous night’s recalled avoidance feedback, b) total number of times the device fell off, c) average shoulder or neck discomfort or pain score resulting from sleeping on back, and d) average effect of position therapy on sleep quality.

PSG reports from 363 consecutive patients evaluated by PSG for various reasons at the study site during the 150-day study recruitment period (but not enrolled to the study) were retrospectively analyzed to assess the prevalence of positional sleep apnea in the patient sample from which this study cohort was selected. Supine and non-supine AHI were calculated for all patients with at least twenty minutes of sleep in both positions, and the percentage of patients with the supine to non-supine AHI ratio of >2 was determined for each of the standard OSA severity categories based on the overall AHI (very mild: 2 - 4 h\(^{-1}\); mild: 5 - 14 h\(^{-1}\); moderate: 15 - 29 h\(^{-1}\); severe: 30 - 59 h\(^{-1}\), and very severe: >60 h\(^{-1}\)).

**RESULTS:**

Thirty-six subjects were initiated into the study. All but one subject wore the NPTD during their baseline study. Five subjects were dropped as a result of their baseline PSG results. Two had very severe sleep disordered breathing with an overall to non-supine ratio < 1.5, two had an overall AHI <5, and one had <4-hours of sleep time. One subject was dropped for protocol non-compliance due to failure to maintain and submit daily sleep diaries. Of the 22 males and eight females who completed the protocol, 37% had mild overall OSA severity (AHI >5 and <15), 33% had moderate overall severity (AHI >15 and <30), and 30% had overall severe OSA (AHI >30).

**Primary Endpoints:**
**Respiratory Measures**: Based on effectiveness of the supine sleep restriction, the overall and supine AHI, apnea index, and percent time SpO2 < 90% were significantly reduced (Table 1). Across all participants, the mean percent reduction in AHI was 69% and the median reduction was 79%. At follow-up, 73% percent of participants achieved an AHI < 10 with a $\geq50\%$ reduction in overall AHI, and an additional 17% showed potentially important reductions in overall AHI of 50% or 35% (Table 2). Three non-responders exhibited $>60\%$ increase in non-supine AHI at follow-up.

Notable reductions in loud snoring were, on average, achieved with the NPTD as a result of supine position avoidance. Fifty-nine percent of participants exhibited reductions in the percent of time with loud snoring of $\geq5\%$ or more, while only 10% of subjects had an increase in the percent of time with loud snoring. The reduction in loud snoring was statistically significant in those with a baseline apnea index < 10 ($n = 17$, $p=0.04$) but not for the 12 participants with an apnea index $\geq10$.

**Sleep Architecture Measures**: Compared to the baseline PSG, a significant reduction in the percent time Stage N1, decrease in the number of cortical arousals and awakenings per hour of sleep, and a significant increase in Stage N2 sleep were observed. Positive trending improvements in the percent of sleep time in stage REM and sleep efficiency were also noted. A significant increase in the number of supine attempts/hr was observed during the follow-up PSG when positional feedback was delivered. The relationship between cortical arousals and positional feedback attempts per hour is presented in Figure 3.

**Subjective Measures**: The impact of four-weeks of position therapy on subjectively measured impairment and quality of life are presented in Table 4. Subjects showed a significant improvement in depression scores, and marginally significant improvements in ESS, POMS and ISI.
**Secondary Endpoints:**

**Supine Detection:** The NPTD measures of the percent of recording time spent in the supine position were in close agreement with the percent of time supine determined by video inspection of the 29 baseline and 30 follow-up studies (Fig. 2). For the baseline PSG records, three cases had an absolute difference between neck supine and chest plus video supine >5%. For the follow-up studies, NPTD estimates were within 5% of values based on the chest sensor plus video in 28 of 30 studies. Larger disagreements between the PSG and NPTD estimates occurred in patients who spent a portion of the night with the head turned far to the side while the torso was supine. Incorrect detection of supine sleep which would result in non-delivery of therapy for >5% of sleep time was limited to 2 of 59 cases (3%).

**Sleep/Wake Detection:** Table 5 presents the mean sensitivity (sleep) and specificity (wake) of neck actigraphy as compared to PSG. Significant improvements in overall accuracy were observed during the follow-up PSG when positional feedback was delivered.

Differences in total sleep time (TST), sleep efficiency (SE), sleep onset (SO) and wake after sleep onset (WASO) are presented in Bland-Altman plots (Figure 4). No statistically significant differences between PSG and NPTD were observed during either the baseline or the follow-up for TST, SE, SO and WASO. Variability about the mean was reduced by over one-third for TST, SE and WASO when therapy was delivered during the follow-up PSG.

**Supporting Evidence:**
NPTD Home Use: Across subjects, the device was worn in 99% of the possible treatment nights with a median compliance rate of 96% (range 71 to 100%). Twenty-seven of 30 subjects maintained the non-supine position over more than > 98% of the time across nights of use; the remaining three spent 96%, 93% and 84% of the time in bed in the non-supine position. The mean number of supine attempts per night trended lower across the four weeks of treatment but no consistent pattern suggesting a training effect was apparent. Most did not require delivery of the maximum feedback intensity (i.e., max alert) to change positions. The participants were in general not awakened by the feedback, as they recalled only one third of all stimuli delivered (median: 2; range 1 – 4). Repeated measures ANOVA showed that the compliance measures did not significantly vary throughout the four weeks of treatment (Table 5). The average number of perceived stimuli per night also did not change over time.

How the NPTD was adjusted for larger necks may have influenced how often it fell off during the night. Twenty subjects reported the NPTD remained in place during sleep without incident across the four weeks of therapy (neck size 39 ± 3.8 cm). Two reported the device fell off once, and six subjects reported the NPTD fell off between two and four times (neck sizes ranged from 39 to 45.7 cm). One subjects with a neck circumferences of 44 cm reported the device fell off nine times in the first two weeks and 11 times overall. Another subject with a neck circumference of 44.5 cm reported the device fell off 12 times in weeks three and four, and a total of 16 times.

In total, six patients reported symptoms of minor back, shoulder, or neck discomfort in the morning across two or more weeks of therapy. Of these, one subject identified noticeable/extreme back, shoulder, or neck pain across the first two weeks of therapy. A second participant experienced noticeable/extreme pain during week three. All remained in the study until completion.

Across all subjects and nights, the percentage of occurrences that perceived sleep quality was worse/substantially worse as a result of Night Shift trended downward from 13.4% in week 1, 10.2 in week 2, 9.5% in week 3, and 7.4% in week 4.
Prevalence of POSA: Of the 363 PSG reports available for the retrospective analysis, 26 (7%) had an AHI <2 and 128 (35%) had less than 20 minutes of sleep time in either supine or non-supine position; thus, a total of 209 reports were ultimately used for the assessment of POSA prevalence. Table 6 presents the prevalence distributions stratified by and across OSA severities, with the accompanying group AHI distributions. The prevalence of POSA was consistently > 70% across all severity categories, other than those with very severe OSA (the AHI was <60 in over 80% of the studies). Additional statistical analyses showed no evidence of a significant relationship in this sample between the presence/absence of POSA and variables such as age, BMI, total sleep time or total time spent in the supine position.

DISCUSSION:

Several recent studies demonstrated success with supine avoidance therapy when enrollment was limited to mild and moderate OSA. To our knowledge, this is the first study that demonstrated consistent improvement in sleep disordered breathing and sleep architecture across patients with mild, moderate and severe POSA. In this cohort, the mean reduction of overall AHI was 69% and the median reduction was 79%. Eighty-three percent of participants with POSA achieved at least a 50% reduction in overall AHI, 80% met Sher et al.’s criteria for surgical success (i.e., 50% reduction in AHI and post-treatment AHI <20 h⁻¹), and 73% demonstrated a 50% reduction in AHI with a post-treatment AHI <10 h⁻¹. One should note that the percentage of patients with a >50% reduction in AHI was similar in all OSA severity categories. Of interest, 78% of those with severe OSA exhibited a notable decrease in non-supine AHI at follow-up, a pattern that was not consistently observed in those with mild to moderate OSA.

Sleep quality during the course of positional therapy is an important outcome measure, since positional therapy has the potential to disrupt sleep and reduce total sleep time (especially among the
elderly who, once awakened, might have problems falling back to sleep). The quality of sleep (as judged by TST, SE, number of arousals, and percentage of shallow N1 sleep) clearly improved when the NPTD was used. The reduction in sleep disordered breathing contributed to deeper and more efficient sleep. These findings suggest that vibro-tactile positional feedback does not significantly disrupt sleep architecture, or more precisely, that the number of eventual disruptions triggered by the delivery of feedback is vastly eclipsed by disruptions attributed to obstructive supine sleep. As expected, improved sleep quality contributed to clinically relevant downward trend in daytime somnolence, symptoms associated with depression and insomnia, and improved quality of life.

It is difficult to explain why significant improvements in sleep architecture and sleep continuity only contributed to modest improvements in subjective scores. Applying an ESS change $\geq 2$ as a clinically relevant threshold, subjective sleepiness did not increase in any of the study participants, 83% of those with an ESS $\leq 7$ and 73% of those with an ESS $> 13$ reported an improvement. However only 15% with an ESS between 8 and 12 reported ESS improvements of 2 or more. Of the six subjective measures we evaluated, the FOSQ showed the least statistical improvement. A moderate association was observed between the ESS and depression change scores ($r=0.63$, $p< 0.001$).

In a comparable study, Van Mannan$^{10}$ found no significant differences in the PSG-derived data but noted significant improvements in ESS and FOSQ responses after 30-days of position therapy. In both studies, 50% of participants exhibited an ESS improvement of 2 or more. In the Van Mannan cohort, the ESS improvements were more equally distributed across ESS ranges. Differences in the two studies with respect to improvement of the FOSQ are difficult to explain other than patients living in Southern California reported improved quality of life scores before and after the study, with less group variability, than those living in the Netherlands.

Of the three subjects who were totally non-responsive to the NPTD, night to night variability in post-treatment AHI$^{17,18}$ was likely a contributing factor in two cases. Both subjects exhibited $> 60%$
increase non-supine AHI compared to baseline, yet reported substantial improvements in FOSQ and other subjective scores, after four weeks of position avoidance therapy. Given these findings, it would be beneficial to cross-validate the NPTD with a sham controlled study in a larger, more diverse population.

Ten percent of the subjects in this study slept greater than 5% supine when supine-avoidance feedback was delivered; as compared to 29% for the Van Maanan cohort.\textsuperscript{10} This discrepancy is likely attributed to differences in the two approaches used for delivery of supine avoidance feedback. The NPTD will not initiate feedback for 15-minutes after the device is turned on and for five minutes after any sustained upright period greater than one-minute. The chest-device delays feedback for 30-minutes after being turned on, and again for 30-minutes after any sustained upright time. The occurrences of false-negative delivery of vibro-tactile therapy (i.e., percent supine errors greater than 5%) were similar for the NPTD (i.e., 2 of 59 cases) and torso supine sleep reported by Bignold et al.\textsuperscript{11} (i.e., 1 of 15 cases). In all three studies, subjects were accepting of vibro-tactile feedback and compliant in its use.

While patient selection clearly contributes to position therapy efficacy, where the supine position is detected and how feedback is delivered may also impact outcomes. Van Kersteren et al.\textsuperscript{19} demonstrated that subtle changes in head position which are not reported by torso position have clinically important implications for OSA severity. The NPTD ensures that positions most vulnerable to airway collapse due to the effects of gravity are avoided. The NPTD avoids delivery of feedback when the chest is supine and the neck is upright so users can read or watch television in bed with the device turned on to avoid falling asleep without therapy.

The definition of POSA used in this study was selected as a result of the FDA requirement that the NPTD demonstrate a 50% reduction in overall AHI. The classic definition of POSA (i.e., supine AHI at least two times greater than the non-supine AHI), does not consider the impact of supine sleep time and/or supine AHI severity in its contribution to the overall AHI. Rather than create a sophisticated
algorithm to screen for various combinations of supine AHI severities and durations, we utilized an alternative criteria whereby the overall AHI had to be at least 1.5 times greater than the non-supine AHI for our enrollment. To demonstrate these alternative criteria did not bias the results, we compared the two POSA definitions using the data provided in Table 6. The net difference was to reclassify six percent of patients with an AHI < 15 (8 of 132), and 2% of patients with an AHI ≥ 15 as non-positional vs. the classic definition of POSA. This does, however, suggest the NPTD would likely be much less useful for OSA patients who already have the habit of sleeping in the non-supine position. In retrospect, the classic definition of POSA\textsuperscript{2,6,10} is preferable so long as the contribution of the supine sleep disordered breathing on the overall AHI is considered in combination with the selected SpO2 desaturation criteria. As compared to a 4% desaturation, a 3% reduction in oxyhemoglobin desaturation will result in a greater number of hypopnea events being identified. If the increase in non-supine events occurs at a greater rate than supine events, then alternative definitions of POSA may be necessary.

Using the classic definition, POSA prevalence at our study site was approximately 5% greater than previous reports\textsuperscript{1,3}. The percentage of patients with POSA and mild OSA was identical to Benoist\textsuperscript{5} (72.9 vs. 73.3%, respectively), and very close for moderate OSA (74.1% and 78.1%, respectively). We chose to evaluate the POSA prevalence with severe and very severe OSA and found that POSA was distributed quite similarly across all AHI severities < 60. When our severe and very severe OSA groups were combined, the POSA prevalence for those with an AHI ≥ 30 was greater than for Benoist (41.1% vs. 30.0, respectively). The percentage of PSG studies which could not be classified due to insufficient supine or non-supine sleep time was equivalent to another POSA prevalence report\textsuperscript{3}. Unfortunately, due to the overwhelming directive toward CPAP therapy, it is common for OSA diagnostic studies to be conducted with an insufficient assessment of positional severity. In some cases, home sleep testing devices are used that do not measure position\textsuperscript{20}, and in other cases split-night PSG studies are performed with insufficiently recorded amounts of supine or non-supine sleep time.\textsuperscript{3} Given the
influence positional severity has on outcomes across all OSA therapies,\textsuperscript{2,21} it raises the question as to why the adequate characterization of positional OSA severity is an option, rather than a requirement, for the delivery of an acceptable OSA diagnostic study.

A BMI $\leq 35$ was used an inclusion criteria as a precaution for potential neck and shoulder problems that might have resulted from increased non-supine sleep in those morbidly obese. Several of the studied subjects complained of minor shoulder or neck soreness as a result of increased non-supine sleep; however the discomfort was insufficient to withdraw from the study. A post-hoc analysis confirmed there was no relationship between increased BMI and complaints of discomfort. Although the BMI criteria resulted in exclusion of a quarter of potential candidates from the study site, an analysis of the POSA prevalence data stratified for BMI $> 35$ suggested greater bias toward non-positional OSA, although the sample size of high BMI individuals (n=53) was small. Because supine avoidance feedback is delivered to the neck rather than the torso, there is no obvious reason why an obese POSA patient would not be effectively treated with the NPTD. Additional investigations are needed to evaluate efficacy and potential side effects with the NPTD used on larger patients. Additionally, it may be useful to develop a questionnaire to help identify patients with histories of neck or back issues that might be exclusion criteria for position therapy.

In this study, 45\% of those with mild OSA, 11\% with moderate OSA and 56\% with severe OSA had at least a 10\% reduction in the frequency of loud snoring. The significant reduction in loud snoring (defined as at least one snore in a 30-second epoch $> 50$ dB) reported in this study conflicts with Bignold et al. report that supine avoidance does not reduce snoring.\textsuperscript{11} Differences in the characterization of loud snoring (i.e., 50 dB vs. 70 dB) were likely attributed to differences in the measurement with an acoustic microphone at the neck vs. nasal prongs. The NPTD automatically excluded loud sounds acquired when actigraphy-based wake or upright times which were likely equivalent to the hand scoring of intensity employed by Bignold. The finding that over half of the patients with an apnea index $< 10$ exhibited an
important reduction in snoring was consistent with Ravesloot’s conclusion.\textsuperscript{2} Given that changes in loud snoring may be most useful in assessing the benefit of supine avoidance therapy in benign snorers, additional studies should be conducted to evaluate the benefit of position therapy in those who exhibit insufficient sleep disordered breathing during their diagnostic study to qualify for healthcare system provided OSA therapy.

The NPTD sensitivity to the detection of sleep improved slightly and its specificity with respect to detection of wake improved considerably during the follow-up PSG when subjects were delivered supine avoidance therapy. It is common for Bland-Altman plots comparing actigraphy to PSG to distribute most of the results above the zero line, indicating the bias toward over-reporting of sleep. Differences between NPTD and PSG were equally distributed above and below the zero line for TST, SE, and WASO. The initial under-reporting of SO was a result of automatic assignment of wake to the first 10 minutes after the device is turned on.

One of the important advantages of the NPTD, as compared to pillow-based position therapy devices, is the capability to monitor compliance and efficacy. Based on the percent time supine, number of supine attempts/night, number of times maximum feedback was required, and the average response to feedback, these data suggest subjects do not acclimate and become non-responsive to vibro-tactile feedback. These findings suggest, but do not definitively prove, the treatment outcomes were a result of the therapeutic impact of the device and not a training/behavioral effect. We found that those who responded slowly to feedback remained slow responders across the treatment period.

To overcome one of the limitations of this study, an evaluation is underway to assess long term compliance with the NPTD. This study will allow us to assess changes in subjective measures and compliance across a six-month observation window. This study will also allow us to evaluate whether one can become behaviorally trained to avoid the supine position without feedback,\textsuperscript{22} or if position therapy will need to be delivered nightly to be effective, as with other OSA treatments. Another study is
underway to evaluate the benefit of positional therapy in combination with sub-optimal outcomes resulting from oral appliance therapy.

It is often presumed that that CPAP should be offered as the initial treatment option across all OSA severity ranges and only patients with mild to moderate sleep disordered breathing who are non-compliant with CPAP are candidates for a position therapy (or other non-CPAP treatment). To challenge this conventional thinking, a randomized trial is required with control groups having either NPTD or CPAP. Endpoints based on utilization and subjective outcomes would be justified based on the assumption that a treatment that is 60% effective and used 100% of the time by a majority of patients may be more useful than a treatment that is 100% effective but used only 40% of the time by only half of the patients. The results from such a study, in combination with better profiling of patients during the diagnostic study, might contribute to adoption of a wider range of initial treatment options or combinations of therapy, and improved long-term outcomes.

ACKNOWLEDGEMENTS: The authors wish to thank the staff at Complete Sleep Solutions for their assistance with subject recruitment, Kara Henninger for her assistance with recruitment, and Delmer Henninger, M.D., ABSM, James Smith, RPSGT and Glen Edwards, RPSGT for their scoring and video editing. Additionally, the contributions of Brastislav Veljkovic, Zoran Matic and Milenko Cventinovic were essential to the development of the NPTD.
FIGURE LEGENDS:

Figure 1. Photograph of neck-device from a. back and b. front.

Figure 2. Bland Altman Plot comparing the percent of time supine as scored by video editing of the chest sensor to the percent of time supine determined with the NPTD.

Figure 3: Comparison of cortical arousals and supine attempts per hour during the follow-up PSG.

Figure 4: Bland-Altman plots comparing PSG to NPTD for: a. total sleep time (TST), b. sleep efficiency (SE), c. sleep onset (SO), and d. wake after sleep onset (WASO).
Table 1: Sleep and respiratory measures obtained by PSG without and with position avoidance feedback

<table>
<thead>
<tr>
<th>Mean ± SD unless noted</th>
<th>Baseline</th>
<th>Follow-up</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male sex, % (n)</td>
<td>73% (22)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age, years</td>
<td>51 ± 9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BMI, kg/M²</td>
<td>28 ± 3.4</td>
<td>28 ± 3.4</td>
<td>N/A</td>
</tr>
<tr>
<td>Time supine, %</td>
<td>46.4 ± 12.7</td>
<td>2.2 ± 6.1</td>
<td>&lt;0.00001</td>
</tr>
<tr>
<td>Overall AHI, events/hr</td>
<td>24.7 ± 14.7</td>
<td>7.5 ± 7.7</td>
<td>&lt;0.00001</td>
</tr>
<tr>
<td>Supine AHI, events/hr</td>
<td>44.9 ± 25.5</td>
<td>4.5 ± 12.7</td>
<td>&lt;0.00001</td>
</tr>
<tr>
<td>Non-supine AHI, events/hr</td>
<td>8.1 ± 7.9</td>
<td>7.1 ± 7.8</td>
<td>0.300</td>
</tr>
<tr>
<td>Apnea Index events/hr</td>
<td>12.1 ± 11.3</td>
<td>2.3 ± 3.9</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>% time SpO2 &lt; 90%</td>
<td>4.2 ± 5.1</td>
<td>1.2 ± 2.1</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Arousal Index, hr</td>
<td>31.9 ± 15.4</td>
<td>19.7 ± 11.3</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Awakenings, hr</td>
<td>5.9 ± 3.2</td>
<td>4.4 ± 1.7</td>
<td>0.015</td>
</tr>
<tr>
<td>Total sleep time, min</td>
<td>353 ± 54.1</td>
<td>369 ± 46.3</td>
<td>0.119</td>
</tr>
<tr>
<td>Stage N1, %</td>
<td>37.3 ± 15.4</td>
<td>23.1 ± 10.9</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Stage N2, %</td>
<td>45.3 ± 11.8</td>
<td>57.4 ± 8.6</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Stage N3, %</td>
<td>5.8 ± 7.3</td>
<td>5.9 ± 6.2</td>
<td>0.493</td>
</tr>
<tr>
<td>Stage REM, %</td>
<td>11.5 ± 5.5</td>
<td>13.7 ± 5.1</td>
<td>0.057</td>
</tr>
<tr>
<td>Sleep efficiency, %</td>
<td>80.9 ± 11.9</td>
<td>85.1 ± 7.6</td>
<td>0.051</td>
</tr>
<tr>
<td>% time snoring &gt; 50 dB</td>
<td>39.5 ± 28.7</td>
<td>26.4 ± 25.0</td>
<td>0.034</td>
</tr>
<tr>
<td>Supine attempts, hr</td>
<td>0.9 ± 0.5</td>
<td>1.2 ± 0.7</td>
<td>0.029</td>
</tr>
<tr>
<td>Values listed: % of total (n)</td>
<td>Mild &lt;5 AHI &lt;15</td>
<td>Moderate &gt;15 AHI &lt; 30</td>
<td>Severe AHI &gt; 30</td>
</tr>
<tr>
<td>--------------------------------------------</td>
<td>----------------</td>
<td>-----------------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>Group size, n</td>
<td>11</td>
<td>10</td>
<td>9</td>
</tr>
<tr>
<td>AHI &lt;10 and &gt;50% decrease</td>
<td>81.8 (9)</td>
<td>80.0 (8)</td>
<td>55.6 (5)</td>
</tr>
<tr>
<td>AHI &gt;50% reduction</td>
<td>0.0 (0)</td>
<td>0.0 (0)</td>
<td>33.3 (3)</td>
</tr>
<tr>
<td>AHI &gt;35% reduction</td>
<td>9.1 (1)</td>
<td>0.0 (0)</td>
<td>11.1 (1)</td>
</tr>
<tr>
<td>Non-responder</td>
<td>9.1 (1)</td>
<td>20.0 (2)</td>
<td>0.0 (0)</td>
</tr>
</tbody>
</table>
Table 3: Subjective measures obtained by questionnaire

<table>
<thead>
<tr>
<th></th>
<th>All values mean + SD</th>
<th>Pre-treatment</th>
<th>Post-treatment</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daytime somnolence - ESS</td>
<td>11.3 ± 4.6</td>
<td>9.5 ± 4.6</td>
<td>0.064</td>
<td></td>
</tr>
<tr>
<td>Quality of Life - FOSQ</td>
<td>93.8 ± 17.4</td>
<td>98.2 ± 16.5</td>
<td>0.158</td>
<td></td>
</tr>
<tr>
<td>Quality of Life - POMS</td>
<td>57.0 ± 21.6</td>
<td>49.1 ± 18.9</td>
<td>0.068</td>
<td></td>
</tr>
<tr>
<td>Depression – PHQ-9</td>
<td>7.0 ± 5.0</td>
<td>8.9 ± 5.4</td>
<td>0.027</td>
<td></td>
</tr>
<tr>
<td>Insomnia - ISI</td>
<td>11.0 ± 5.6</td>
<td>8.9 ± 5.4</td>
<td>0.066</td>
<td></td>
</tr>
<tr>
<td>Anxiety – GAD-7</td>
<td>4.4 ± 4.0</td>
<td>3.3 ± 3.9</td>
<td>0.157</td>
<td></td>
</tr>
</tbody>
</table>
Table 4: Compliance information obtained across four weeks of in-home use

<table>
<thead>
<tr>
<th>Median (mean + SD)</th>
<th>Week 1</th>
<th>Week 2</th>
<th>Week 3</th>
<th>Week 4</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Supine attempts/night</td>
<td>6 (6.9 ± 4.0)</td>
<td>6 (6.7 ± 4.8)</td>
<td>5 (6.3 ± 3.6)</td>
<td>5 (5.7 ± 3.7)</td>
<td>0.684</td>
</tr>
<tr>
<td>Average days used</td>
<td>7 (6.9 ± 0.4)</td>
<td>7 (7.0 ± 0.2)</td>
<td>7 (6.8 ± 0.5)</td>
<td>7 (7.0 ± 0.2)</td>
<td>0.240</td>
</tr>
<tr>
<td>Average compliant days used</td>
<td>7 (6.7 ± 0.7)</td>
<td>7 (6.6 ± 0.6)</td>
<td>7 (6.5 ± 0.7)</td>
<td>7 (6.5 ± 0.9)</td>
<td>0.868</td>
</tr>
<tr>
<td>Average hours used</td>
<td>6.7 (7.2 ± 1.3)</td>
<td>6.9 (7.0 ± 1.4)</td>
<td>7.1 (7.1 ± 1.2)</td>
<td>6.8 (7.0 ± 1.3)</td>
<td>0.934</td>
</tr>
<tr>
<td>Average percent time supine</td>
<td>0.8 (1.7 ± 2.0)</td>
<td>0.7 (2.2 ± 4.6)</td>
<td>0.6 (1.8 ± 3.1)</td>
<td>0.6 (1.8 ± 3.5)</td>
<td>0.957</td>
</tr>
<tr>
<td>Average % time snoring &gt; 50 dB</td>
<td>8.8 (25 ± 29.5)</td>
<td>11.7 (25 ± 26.1)</td>
<td>12.6 (26 ± 27.3)</td>
<td>13.5 (26 ± 26.4)</td>
<td>0.999</td>
</tr>
<tr>
<td>Ave. feedback duration (sec)</td>
<td>12 (26 ± 26.5)</td>
<td>12 (22 ± 19.0)</td>
<td>10 (20 ± 29.3)</td>
<td>10 (19 ± 28.4)</td>
<td>0.741</td>
</tr>
<tr>
<td>Nights with at least 1 max alert</td>
<td>0 (2.4 ± 2.0)</td>
<td>0 (1.8 ± 2.3)</td>
<td>0 (1.4 ± 1.7)</td>
<td>0 (1.6 ± 2.2)</td>
<td>0.363</td>
</tr>
</tbody>
</table>
Table 5: Measures of behavioral sleep/wake by neck actigraphy vs. PSG

<table>
<thead>
<tr>
<th>Mean + SD</th>
<th>Baseline</th>
<th>Follow-up</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sensitivity - sleep</td>
<td>90.1 ± 8.6</td>
<td>91.2 ± 8.1</td>
<td>0.317</td>
</tr>
<tr>
<td>Specificity – wake</td>
<td>55.8 ± 18.7</td>
<td>61.1 ± 16.8</td>
<td>0.132</td>
</tr>
<tr>
<td>Overall agreement</td>
<td>82.3 ± 9.3</td>
<td>86.5 ± 6.5</td>
<td>0.025</td>
</tr>
</tbody>
</table>
Table 6: Prevalence of POSA stratified by AHI severity

<table>
<thead>
<tr>
<th></th>
<th>Very mild &gt;2 AHI &lt; 5</th>
<th>Mild &gt;5 AHI &lt;15</th>
<th>Moderate &gt;15 AHI 30</th>
<th>Severe &gt;30 AHI &lt; 60</th>
<th>Very Severe AHI &gt;60</th>
<th>Total across severities</th>
</tr>
</thead>
<tbody>
<tr>
<td>POSA: % (group n)</td>
<td>73.9 (23)</td>
<td>72.9 (59)</td>
<td>74.1 (54)</td>
<td>73.5 (34)</td>
<td>10.0 (39)</td>
<td>62.2 (209)</td>
</tr>
<tr>
<td>OSA severity: %</td>
<td>11.0</td>
<td>28.2</td>
<td>25.8</td>
<td>16.3</td>
<td>18.7</td>
<td>100.0</td>
</tr>
<tr>
<td>Supine AHI: mean ± SD</td>
<td>6 ± 1.7</td>
<td>18 ± 12.4</td>
<td>43 ± 21.3</td>
<td>68 ± 24.5</td>
<td>92 ± 20.9</td>
<td>45 ± 35.0</td>
</tr>
<tr>
<td>Non-Sup AHI: mean ± SD</td>
<td>2 ± 1.0</td>
<td>5 ± 5.1</td>
<td>10 ± 8.3</td>
<td>24 ± 14.6</td>
<td>76 ± 26.0</td>
<td>22 ± 29.9</td>
</tr>
</tbody>
</table>
References:


Baseline: Bias -0.2 ± 3.0%
Follow-up: Bias 1.0 ± 1.0%
Fig. 4.a. PSG TST minus ND TST (min)  
Baseline: Bias -9 ± 64 min  
Follow-up: Bias 8 ± 41 min

Fig. 4.b. PSG SE minus ND SE (%)  
Baseline: Bias 4 ± 59 min  
Follow-up: Bias -10 ± 39 min

Fig. 4.c. PSG SO minus ND SO (min)  
Baseline: Bias 5 ± 19 min  
Follow-up: Bias 3 ± 14 min

Fig. 4.d. PSG WASO minus ND WASO (min)  
Baseline: Bias 5 ± 64 min  
Follow-up: Bias 8 ± 41 min

Fig. 4.e. PSG TST + ND TST / 2  
Baseline: Bias -2 ± 14%  
Follow-up: Bias 2 ± 9%

Fig. 4.f. PSG SE + ND SE / 2  
Baseline: Bias -9 ± 64%  
Follow-up: Bias 8 ± 41%